In Silico Evaluation of NO-Sartans against SARS-CoV-2
CONCLUSION: Based on our in silico studies, CLC-1280 (a Valsartan dinitrate) has the potential to be considered as an inhibitor of the SARS-CoV-2 virus. However, further in vitro and in vivo evaluations are necessary for the drug development process.PMID:38445698 | DOI:10.2174/0115701638279362240223070810 (Source: Current Drug Discovery Technologies)
Source: Current Drug Discovery Technologies - March 6, 2024 Category: Drugs & Pharmacology Authors: Negar Omidkhah Farzin Hadizadeh Razieh Ghodsi Prashant Kesharwani Amirhossein Sahebkar Source Type: research
In Silico Evaluation of NO-Sartans against SARS-CoV-2
CONCLUSION: Based on our in silico studies, CLC-1280 (a Valsartan dinitrate) has the potential to be considered as an inhibitor of the SARS-CoV-2 virus. However, further in vitro and in vivo evaluations are necessary for the drug development process.PMID:38445698 | DOI:10.2174/0115701638279362240223070810 (Source: Current Drug Discovery Technologies)
Source: Current Drug Discovery Technologies - March 6, 2024 Category: Drugs & Pharmacology Authors: Negar Omidkhah Farzin Hadizadeh Razieh Ghodsi Prashant Kesharwani Amirhossein Sahebkar Source Type: research
In Silico Evaluation of NO-Sartans against SARS-CoV-2
CONCLUSION: Based on our in silico studies, CLC-1280 (a Valsartan dinitrate) has the potential to be considered as an inhibitor of the SARS-CoV-2 virus. However, further in vitro and in vivo evaluations are necessary for the drug development process.PMID:38445698 | DOI:10.2174/0115701638279362240223070810 (Source: Current Drug Discovery Technologies)
Source: Current Drug Discovery Technologies - March 6, 2024 Category: Drugs & Pharmacology Authors: Negar Omidkhah Farzin Hadizadeh Razieh Ghodsi Prashant Kesharwani Amirhossein Sahebkar Source Type: research
In Silico Evaluation of NO-Sartans against SARS-CoV-2
CONCLUSION: Based on our in silico studies, CLC-1280 (a Valsartan dinitrate) has the potential to be considered as an inhibitor of the SARS-CoV-2 virus. However, further in vitro and in vivo evaluations are necessary for the drug development process.PMID:38445698 | DOI:10.2174/0115701638279362240223070810 (Source: Current Drug Discovery Technologies)
Source: Current Drug Discovery Technologies - March 6, 2024 Category: Drugs & Pharmacology Authors: Negar Omidkhah Farzin Hadizadeh Razieh Ghodsi Prashant Kesharwani Amirhossein Sahebkar Source Type: research
Association Between Use of Sodium-Glucose Cotransporter-2 Inhibitors or Angiotensin Receptor-Neprilysin Inhibitor and the Risk of Atherosclerotic Cardiovascular Disease With Coexisting Diabetes and Heart Failure
CONCLUSION: The study suggests that the use of SGLT2 inhibitors, alone or in combination with Entresto, may be effective in reducing the risk of ASCVD and its associated adverse outcomes in patients with diabetes and heart failure. This finding has important implications for the management of these conditions.PMID:38438119 | DOI:10.1177/10742484241233872 (Source: Atherosclerosis)
Source: Atherosclerosis - March 4, 2024 Category: Cardiology Authors: Ya-Wen Lin Chun-Hsiang Lin Cheng-Li Lin Che-Huei Lin Ming-Hung Lin Source Type: research
Comparative Efficacy of Curative Effects of Sacubitril/Valsartan in HFpEF versus HFrEF Treatment
CONCLUSIONS: Sacubitril/Valsartan demonstrates superior efficacy in improving renal function and enhancing quality of life in HFpEF patients while providing comparable prognostic benefits for HFrEF patients. This finding underscores its potential as a therapeutic foundation in the management of heart failure across ejection fraction categories.PMID:38430177 (Source: Alternative Therapies in Health and Medicine)
Source: Alternative Therapies in Health and Medicine - March 2, 2024 Category: Complementary Medicine Authors: Yi Li Zifan Zhu Hongbin Liu Source Type: research
Comparative Efficacy of Curative Effects of Sacubitril/Valsartan in HFpEF versus HFrEF Treatment
CONCLUSIONS: Sacubitril/Valsartan demonstrates superior efficacy in improving renal function and enhancing quality of life in HFpEF patients while providing comparable prognostic benefits for HFrEF patients. This finding underscores its potential as a therapeutic foundation in the management of heart failure across ejection fraction categories.PMID:38430177 (Source: Alternative Therapies in Health and Medicine)
Source: Alternative Therapies in Health and Medicine - March 2, 2024 Category: Complementary Medicine Authors: Yi Li Zifan Zhu Hongbin Liu Source Type: research
Comparative Efficacy of Curative Effects of Sacubitril/Valsartan in HFpEF versus HFrEF Treatment
CONCLUSIONS: Sacubitril/Valsartan demonstrates superior efficacy in improving renal function and enhancing quality of life in HFpEF patients while providing comparable prognostic benefits for HFrEF patients. This finding underscores its potential as a therapeutic foundation in the management of heart failure across ejection fraction categories.PMID:38430177 (Source: Alternative Therapies in Health and Medicine)
Source: Alternative Therapies in Health and Medicine - March 2, 2024 Category: Complementary Medicine Authors: Yi Li Zifan Zhu Hongbin Liu Source Type: research
Comparative Efficacy of Curative Effects of Sacubitril/Valsartan in HFpEF versus HFrEF Treatment
CONCLUSIONS: Sacubitril/Valsartan demonstrates superior efficacy in improving renal function and enhancing quality of life in HFpEF patients while providing comparable prognostic benefits for HFrEF patients. This finding underscores its potential as a therapeutic foundation in the management of heart failure across ejection fraction categories.PMID:38430177 (Source: Alternative Therapies in Health and Medicine)
Source: Alternative Therapies in Health and Medicine - March 2, 2024 Category: Complementary Medicine Authors: Yi Li Zifan Zhu Hongbin Liu Source Type: research
Comparative Efficacy of Curative Effects of Sacubitril/Valsartan in HFpEF versus HFrEF Treatment
CONCLUSIONS: Sacubitril/Valsartan demonstrates superior efficacy in improving renal function and enhancing quality of life in HFpEF patients while providing comparable prognostic benefits for HFrEF patients. This finding underscores its potential as a therapeutic foundation in the management of heart failure across ejection fraction categories.PMID:38430177 (Source: Alternative Therapies in Health and Medicine)
Source: Alternative Therapies in Health and Medicine - March 2, 2024 Category: Complementary Medicine Authors: Yi Li Zifan Zhu Hongbin Liu Source Type: research
Comparative Efficacy of Curative Effects of Sacubitril/Valsartan in HFpEF versus HFrEF Treatment
CONCLUSIONS: Sacubitril/Valsartan demonstrates superior efficacy in improving renal function and enhancing quality of life in HFpEF patients while providing comparable prognostic benefits for HFrEF patients. This finding underscores its potential as a therapeutic foundation in the management of heart failure across ejection fraction categories.PMID:38430177 (Source: Alternative Therapies in Health and Medicine)
Source: Alternative Therapies in Health and Medicine - March 2, 2024 Category: Complementary Medicine Authors: Yi Li Zifan Zhu Hongbin Liu Source Type: research
Comparative Efficacy of Curative Effects of Sacubitril/Valsartan in HFpEF versus HFrEF Treatment
CONCLUSIONS: Sacubitril/Valsartan demonstrates superior efficacy in improving renal function and enhancing quality of life in HFpEF patients while providing comparable prognostic benefits for HFrEF patients. This finding underscores its potential as a therapeutic foundation in the management of heart failure across ejection fraction categories.PMID:38430177 (Source: Alternative Therapies in Health and Medicine)
Source: Alternative Therapies in Health and Medicine - March 2, 2024 Category: Complementary Medicine Authors: Yi Li Zifan Zhu Hongbin Liu Source Type: research
Correction to: Effect of sacubitril valsartan on heart failure with mid-range or preserved ejection fraction in patients on maintenance hemodialysis: real-world experience in a single-center, prospective study
(Source: BMC Cardiovascular Disorders)
Source: BMC Cardiovascular Disorders - March 2, 2024 Category: Cardiology Authors: Xiao-mei Huang, Jing-jing Li, Wang Yin, Hui-ling Fu, Fen Yu, Lian-qing Gu, Yi Zhang, Min Du, Zheng Ye and Li Xu Tags: Correction Source Type: research
Comparative effectiveness of sacubitril/valsartan versus angiotensin receptor blockers in patients with heart failure with preserved ejection fraction: A real-world study
CONCLUSION: Among individuals with private or Medicare Advantage insurance plans, there was no significant difference in the risk of HF-related hospitalization or all-cause hospitalization between adults with HFpEF who received SAC/VAL and those who received ARB therapy.PMID:38427969 | DOI:10.1093/ajhp/zxae053 (Source: American Journal of Health-System Pharmacy : AJHP)
Source: American Journal of Health-System Pharmacy : AJHP - March 1, 2024 Category: Drugs & Pharmacology Authors: Munaza Riaz Steven M Smith Eric A Dietrich David E Winchester Jingchuan Guo Haesuk Park Source Type: research
Comparative effectiveness of sacubitril/valsartan versus angiotensin receptor blockers in patients with heart failure with preserved ejection fraction: A real-world study
CONCLUSION: Among individuals with private or Medicare Advantage insurance plans, there was no significant difference in the risk of HF-related hospitalization or all-cause hospitalization between adults with HFpEF who received SAC/VAL and those who received ARB therapy.PMID:38427969 | DOI:10.1093/ajhp/zxae053 (Source: American Journal of Health-System Pharmacy : AJHP)
Source: American Journal of Health-System Pharmacy : AJHP - March 1, 2024 Category: Drugs & Pharmacology Authors: Munaza Riaz Steven M Smith Eric A Dietrich David E Winchester Jingchuan Guo Haesuk Park Source Type: research
